Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of RLY-2608 in PIK3CA-related overgrowth spectrum and PIK3CA-driven malformations
2024-518895-30-00Phase 2Authorised
- Sponsor
- Relay Therapeutics
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of zovegalisib in PIK3CA-related overgrowth spectrum (PROS) and vascular malformation (3 arms), sponsored by Relay Therapeutics. Primary endpoints: Recommended phase 2 dose, Overall safety profile and 1 more. Planned start Nov 2025; status: authorised.
02
Drugs
zovegalisib
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)vascular malformation
Beyond the preview
Go deeper on 2024-518895-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518895-30-00.